IASLC > International Association for the Study of Lung Cancer > About IASLC > News Detail

Dr. Nir Peled Joins the IASLC Board

Friday, November 15, 2019

Nir Peled637094322236271878.png

The IASLC is pleased to welcome a new addition to its Board of Directors. Professor Nir Peled, a pulmonologist, medical oncologist and Head of the Cancer Institute, Soroka Medical Center, Ben Gurion University of the Negev, Beer Sheva, Israel, has joined the IASLC Board. An expert in thoracic oncology, Dr. Peled brings a vast amount of experience and expertise to the table. His research focuses are highly diverse, encompassing everything from targeted therapy and immunotherapy to biomarker development and early detection. And he has published nearly 200 peer-reviewed articles and serves on the editorial board for numerous journals – including our own Journal of Thoracic Oncology.

Dr. Peled’s appointment to the Board was made possible following the resignation of Dr. Takashi Seto. Replacing a vacant Board position is an action permissible under the IASLC Bylaws. The association thanks Dr. Seto for his years of service and looks forward to his future contributions to our organization. Dr. Peled will serve out the remainder of Dr. Seto’s term until the IASLC 2021 World Conference on Lung Cancer, which will take place in Denver, Colorado. The IASLC would like to congratulate Dr. Peled on his appointment and for his continued commitment to the association. His presence on the Board of Directors will undoubtedly benefit our operations, programs and membership, allowing us to continue providing value to the communities we serve and ensuring that the IASLC remains the world’s leading lung cancer organization. 


About the Author

Adam Mohrbacher is IASLC’s Communications Manager, responsible for managing the organization’s email communications and social media, and assisting with marketing and public relations efforts.

Adam Mohrbacher, Communications and Marketing Manager